130 related articles for article (PubMed ID: 38885841)
1. Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 52-week multicenter retrospective study.
Sood S; Rimke A; Rankin BD; Abduelmula A; Georgakopoulos JR; Maliyar K; Bagit A; Leung F; Stark LA; Devani AR; Vender R; Yeung J; Prajapati VH
J Am Acad Dermatol; 2024 Jun; ():. PubMed ID: 38885841
[No Abstract] [Full Text] [Related]
2. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis).
Gargiulo L; Narcisi A; Ibba L; Balato A; Bianchi L; Brianti P; Buononato D; Burlando M; Caldarola G; Campanati A; Campione E; Carrera CG; Carugno A; Cristaudo A; Cusano F; Dapavo P; Dattola A; De Simone C; Gaiani FM; Gisondi P; Giunta A; Loconsole F; Maione V; Mortato E; Marzano AV; Maurelli M; Megna M; Mercuri SR; Offidani A; Orsini D; Parodi A; Pellacani G; Potestio L; Quaglino P; Richetta AG; Romano F; Sena P; Venturini M; Malagoli P; Costanzo A
Front Med (Lausanne); 2023; 10():1243843. PubMed ID: 37614958
[TBL] [Abstract][Full Text] [Related]
3. Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study.
Rimke A; Sood S; Rankin BD; Abduelmula A; Georgakopoulos JR; Maliyar K; Bagit A; Leung F; Stark LA; Vender R; Yeung J; Prajapati VH
J Am Acad Dermatol; 2024 Apr; ():. PubMed ID: 38649098
[No Abstract] [Full Text] [Related]
4. Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).
Orsini D; Malagoli P; Balato A; Bianchi L; Brianti P; Buononato D; Burlando M; Caldarola G; Campanati A; Campione E; Carrera CG; Carugno A; Cusano F; Dapavo P; Dattola A; De Simone C; Dini V; Esposito M; Fargnoli MC; Gaiani FM; Gargiulo L; Gisondi P; Giunta A; Ibba L; Lasagni C; Loconsole F; Maione V; Mortato E; Marzano AV; Maurelli M; Megna M; Mercuri SR; Narcisi A; Offidani A; Paolino G; Parodi A; Pellacani G; Potestio L; Quaglino P; Richetta AG; Romano F; Sena P; Venturini M; Assorgi C; Costanzo A
Dermatol Pract Concept; 2024 Apr; 14(2):. PubMed ID: 38416060
[TBL] [Abstract][Full Text] [Related]
5. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A
Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study.
Hagino T; Saeki H; Fujimoto E; Kanda N
J Dermatol; 2024 May; 51(5):649-658. PubMed ID: 38482898
[TBL] [Abstract][Full Text] [Related]
7. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
[TBL] [Abstract][Full Text] [Related]
8. Bimekizumab: Short-Term Effectiveness and Safety in Real Clinical Practice in Andalucia, Spain.
Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Cebolla-Verdugo M; Prados-Carmona A; Hernández-Montoya C; Armario-Hita JC; Galán-Gutiérrez M
Life (Basel); 2024 Feb; 14(3):. PubMed ID: 38541607
[No Abstract] [Full Text] [Related]
9. Bimekizumab versus Secukinumab in Plaque Psoriasis.
Reich K; Warren RB; Lebwohl M; Gooderham M; Strober B; Langley RG; Paul C; De Cuyper D; Vanvoorden V; Madden C; Cioffi C; Peterson L; Blauvelt A
N Engl J Med; 2021 Jul; 385(2):142-152. PubMed ID: 33891380
[TBL] [Abstract][Full Text] [Related]
10. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.
Blauvelt A; Papp KA; Merola JF; Gottlieb AB; Cross N; Madden C; Wang M; Cioffi C; Griffiths CEM
J Am Acad Dermatol; 2020 Nov; 83(5):1367-1374. PubMed ID: 32473974
[TBL] [Abstract][Full Text] [Related]
11. Bimekizumab versus Adalimumab in Plaque Psoriasis.
Warren RB; Blauvelt A; Bagel J; Papp KA; Yamauchi P; Armstrong A; Langley RG; Vanvoorden V; De Cuyper D; Cioffi C; Peterson L; Cross N; Reich K
N Engl J Med; 2021 Jul; 385(2):130-141. PubMed ID: 33891379
[TBL] [Abstract][Full Text] [Related]
12. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.
Strober B; Paul C; Blauvelt A; Thaçi D; Puig L; Lebwohl M; White K; Vanvoorden V; Deherder D; Gomez NN; Eyerich K
J Am Acad Dermatol; 2023 Sep; 89(3):486-495. PubMed ID: 37182701
[TBL] [Abstract][Full Text] [Related]
13. Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting.
Rompoti N; Stefanaki I; Panagakis P; Vavouli C; Politou M; Papoutsaki M; Befon A; Koutsa F; Lazou E; Koumprentziotis IA; Chasapi V; Stratigos A; Nicolaidou E
Arch Dermatol Res; 2024 Apr; 316(5):133. PubMed ID: 38662223
[TBL] [Abstract][Full Text] [Related]
14. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
[TBL] [Abstract][Full Text] [Related]
15. Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study.
Asahina A; Okubo Y; Morita A; Tada Y; Igarashi A; Langley RG; Deherder D; Matano M; Vanvoorden V; Wang M; Ohtsuki M; Nakagawa H
Dermatol Ther (Heidelb); 2023 Mar; 13(3):751-768. PubMed ID: 36648594
[TBL] [Abstract][Full Text] [Related]
16. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials.
Wang Y; Li S; Bai J; Cai X; Tang S; Lin P; Sun Q; Qiao J; Fang H
Ther Adv Chronic Dis; 2023; 14():20406223231163110. PubMed ID: 37051072
[TBL] [Abstract][Full Text] [Related]
17. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.
Oliver R; Krueger JG; Glatt S; Vajjah P; Mistry C; Page M; Edwards H; Garcet S; Li X; Dizier B; Maroof A; Watling M; El Baghdady A; Baeten D; Ionescu L; Shaw S
Br J Dermatol; 2022 Apr; 186(4):652-663. PubMed ID: 34687214
[TBL] [Abstract][Full Text] [Related]
18. Bimekizumab Self-Injection Devices: Two Multicenter, Randomized, Open-Label Studies on Self-Administration by Patients With Psoriasis.
Bagel J; Tatla D; Hellot S; Knapp B; Murphy C; Peterson L; Sebastian M
J Drugs Dermatol; 2022 Feb; 21(2):162-171. PubMed ID: 35133113
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
Thaçi D; Vender R; de Rie MA; Conrad C; Pariser DM; Strober B; Vanvoorden V; Wang M; Madden C; de Cuyper D; Kimball AB
Br J Dermatol; 2023 Jan; 188(1):22-31. PubMed ID: 36689515
[TBL] [Abstract][Full Text] [Related]
20. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
Gordon KB; Langley RG; Warren RB; Okubo Y; Stein Gold L; Merola JF; Peterson L; Wixted K; Cross N; Deherder D; Thaçi D
JAMA Dermatol; 2022 Jul; 158(7):735-744. PubMed ID: 35544084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
